Your browser is no longer supported. Please, upgrade your browser.
TPTX Turning Point Therapeutics, Inc. daily Stock Chart
TPTX [NASD]
Turning Point Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.84 Insider Own3.70% Shs Outstand36.49M Perf Week-11.62%
Market Cap2.13B Forward P/E- EPS next Y-3.22 Insider Trans-22.77% Shs Float29.82M Perf Month-3.26%
Income-56.20M PEG- EPS next Q-0.64 Inst Own84.20% Short Float7.06% Perf Quarter15.78%
Sales- P/S- EPS this Y-49.40% Inst Trans14.30% Short Ratio4.01 Perf Half Y27.35%
Book/sh13.01 P/B4.50 EPS next Y6.90% ROA- Target Price65.00 Perf Year-
Cash/sh4.72 P/C12.38 EPS next 5Y- ROE- 52W Range24.21 - 67.54 Perf YTD-6.12%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-16.58% Beta-
Dividend %- Quick Ratio36.60 Sales past 5Y- Gross Margin- 52W Low132.71% ATR3.05
Employees77 Current Ratio36.60 Sales Q/Q- Oper. Margin- RSI (14)38.42 Volatility5.17% 4.39%
OptionableYes Debt/Eq0.00 EPS Q/Q- Profit Margin- Rel Volume0.23 Prev Close58.48
ShortableYes LT Debt/Eq0.00 EarningsFeb 24 AMC Payout- Avg Volume525.02K Price56.34
Recom1.50 SMA20-7.41% SMA50-6.08% SMA20021.12% Volume85,650 Change-3.66%
Nov-14-19Initiated ROTH Capital Buy $65
Sep-25-19Initiated H.C. Wainwright Buy $70
Sep-10-19Initiated Wedbush Outperform
Jul-24-19Initiated Guggenheim Buy $58
May-13-19Initiated Wells Fargo Outperform
May-13-19Initiated SVB Leerink Outperform $42
May-13-19Initiated RBC Capital Mkts Outperform $48
May-13-19Initiated Goldman Buy $50
Feb-20-20 09:00AM  Turning Point Therapeutics Names Siegfried Reich as Executive Vice President and Chief Scientific Officer GlobeNewswire
Feb-18-20 09:00AM  Turning Point Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire
Feb-03-20 09:00AM  Turning Point Therapeutics to Participate in Guggenheim Oncology Day GlobeNewswire
Jan-23-20 09:00AM  Turning Point Therapeutics Names Garry Nicholson to Its Board of Directors GlobeNewswire
Jan-13-20 09:00AM  Turning Point Therapeutics Announces Program Updates and Milestones for 2020 GlobeNewswire -6.71%
Jan-10-20 07:13AM  The Daily Biotech Pulse: Positive Data Readouts To Spur Aclaris, Moderna And Ultragenyx Benzinga -13.05%
Jan-09-20 05:00PM  Turning Point Therapeutics Announces Management Transition GlobeNewswire
10:01AM  Are Insiders Buying Turning Point Therapeutics, Inc. (NASDAQ:TPTX) Stock? Simply Wall St.
Jan-06-20 09:00AM  Turning Point Therapeutics Names Homa Yeganegi Senior Vice President, Project Team Leader and Head of Medical Affairs GlobeNewswire
Dec-27-19 09:17AM  The Zacks Analyst Blog Highlights: BYND, ZM, KRTX, TPTX and SILK Zacks
Dec-26-19 09:53AM  5 Best Performing IPOs of 2019 Zacks
Dec-23-19 02:30PM  Hedge Funds Have Never Been This Bullish On Turning Point Therapeutics, Inc. (TPTX) Insider Monkey
Dec-17-19 09:00AM  Turning Point Therapeutics to Participate in 38th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-10-19 08:33AM  Turning Point (TPTX) Catches Eye: Stock Jumps 6.1% Zacks
Nov-19-19 07:24AM  Weighing the Risk-Reward in Turning Point Therapeutics TheStreet.com
Nov-13-19 08:30AM  Turning Point Therapeutics to Participate in Upcoming Investor Conferences GlobeNewswire
Nov-12-19 08:30AM  Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of Repotrectinib in Pediatric Patients GlobeNewswire
Nov-11-19 08:30AM  Turning Point Therapeutics Initiates Phase 1/2 Clinical Study of TPX-0046, a Novel RET/SRC Inhibitor GlobeNewswire
Nov-08-19 10:34AM  The Zacks Analyst Blog Highlights: Zoom Video Communications, Beyond Meat, Turning Point Therapeutics and Cortexyme Zacks
Nov-07-19 08:18AM  4 Best-Performing IPOs So Far in 2019 Zacks
Nov-04-19 04:05PM  Turning Point Therapeutics Reports Third Quarter 2019 Financial and Operational Results GlobeNewswire
Oct-28-19 08:03PM  Hedge Funds Have Never Been This Bullish On Turning Point Therapeutics, Inc. (TPTX) Insider Monkey
Oct-21-19 06:00AM  Turning Point Therapeutics to Host Third Quarter 2019 Conference Call GlobeNewswire
Sep-30-19 08:30AM  Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug Application for TPX-0046, a Novel RET/SRC Inhibitor GlobeNewswire
Sep-18-19 10:15AM  Is Failure in Store for the WeWork IPO? InvestorPlace -6.25%
Sep-11-19 07:15PM  Turning Point Therapeutics Inc (TPTX) President & CEO Athena Countouriotis Bought $450,000 ... GuruFocus.com
Sep-09-19 01:57PM  Short Squeeze Candidates: 10 Most Heavily Shorted Stocks Benzinga
Sep-05-19 08:34PM  Turning Point Therapeutics Announces Pricing of Public Offering of Common Stock GlobeNewswire
Sep-03-19 04:14PM  Turning Point Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire -6.46%
04:01PM  Turning Point Therapeutics Announces Updated Interim Clinical Data of Repotrectinib and Preclinical Data for TPX-0046, a Novel RET/SRC Inhibitor GlobeNewswire
Aug-29-19 09:16PM  3 New Biotech Stocks That Keep On Soaring Motley Fool
Aug-28-19 09:00AM  Turning Point Therapeutics Participate in Upcoming Investor Conferences GlobeNewswire +5.63%
Aug-06-19 04:05PM  Turning Point Therapeutics Reports Second Quarter 2019 Financial and Operational Results GlobeNewswire
Aug-01-19 02:31PM  What Kind Of Shareholder Appears On The Turning Point Therapeutics, Inc.'s (NASDAQ:TPTX) Shareholder Register? Simply Wall St.
Jul-31-19 04:30PM  Turning Point Therapeutics CEO to Present at Canaccord Genuity 39th Annual Growth Conference GlobeNewswire
08:30AM  Turning Point Therapeutics Initiates Phase 1 Clinical Study of Tpx-0022, a Novel Met Inhibitor Targeting Advanced Solid Tumors GlobeNewswire
Jul-29-19 08:30AM  Turning Point Therapeutics Appoints Biotechnology Investment Banker Yi Larson as Executive Vice President and Chief Financial Officer GlobeNewswire
Jul-25-19 08:30AM  Turning Point Therapeutics Names Carol Gallagher, Pharm.D. to its Board of Directors GlobeNewswire
Jul-22-19 09:00AM  Turning Point Therapeutics to Host Second Quarter 2019 Conference Call GlobeNewswire
Jun-20-19 09:00AM  Turning Point Therapeutics Initiates Phase 2 Registrational Portion of TRIDENT-1 Clinical Study GlobeNewswire
Jun-18-19 07:09AM  Shares of cancer-therapy companies skyrocket after Pfizer acquisition news MarketWatch
Jun-04-19 08:30AM  Turning Point Therapeutics CEO to Present at Goldman Sachs 40th Annual Global Healthcare Conference GlobeNewswire
May-31-19 08:30AM  Turning Point Therapeutics Announces Updated Interim Clinical Data of Repotrectinib in Advanced ROS1+ Non-Small Cell Lung Cancer GlobeNewswire -10.26%
May-24-19 09:36AM  Bay Area figures prominently in hottest IPOs so far this year American City Business Journals
May-15-19 09:00AM  Turning Point Therapeutics Announces FDA Clearance of Investigational New Drug Application for TPX-0022, a Novel MET/CSF1R/SRC Inhibitor GlobeNewswire
May-14-19 04:30PM  Turning Point Therapeutics' CEO to Present at UBS Healthcare Conference GlobeNewswire
09:00AM  Turning Point Therapeutics Names Biotech Veteran Patrick Machado, J.D. to Its Board of Directors GlobeNewswire
May-06-19 09:00AM  Turning Point Therapeutics and Almac Diagnostic Services Announce Approval of an Investigational Device Exemption for the Companion Diagnostic Assay to the Registrational TRIDENT-1 Clinical Study GlobeNewswire
Apr-29-19 12:57PM  Weekly CEO Buys Highlight GuruFocus.com +5.69%
Apr-24-19 08:15PM  Turning Point Therapeutics Inc (TPTX) President & CEO Athena Countouriotis Bought $216,000 ... GuruFocus.com
Apr-22-19 04:05PM  Turning Point Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Apr-17-19 11:01AM  Turning Point Therapeutics IPO: What You Need To Know Benzinga
Apr-16-19 10:57PM  Turning Point Therapeutics Announces Pricing of Initial Public Offering Business Wire
Apr-14-19 09:53AM  IPO Outlook For The Week: Pinterest, Zoom, Biotechs, Minerals And Catastrophe Insurance Benzinga
Turning Point Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in designing and developing novel small molecule targeted oncology therapies. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naive and TKI-pretreated patients. The company's lead drug candidate repotrectinib (TPX-0005) is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+ or ALK+ advanced solid tumors. Its pipeline also includes multi-targeted drug candidates TPX-0046, a RET/SRC inhibitor; TPX-0022, a MET/CSF1R/SRC inhibitor; and a series of ALK inhibitors. The company was incorporated in 2013 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cui Jingrong JeanDirectorFeb 13Sale61.8411,500711,137781,219Feb 14 04:22 PM
Cui Jingrong JeanDirectorFeb 12Sale65.9218,5001,219,594792,719Feb 12 07:31 PM
Cui Jingrong JeanDirectorFeb 11Sale63.2318,5001,169,668811,219Feb 12 07:31 PM
Cui Jingrong JeanDirectorFeb 10Sale62.9418,5001,164,482829,719Feb 12 07:31 PM
Cui Jingrong JeanChief Scientific OfficerJan 29Sale58.737,000411,104848,219Jan 29 07:37 PM
Cui Jingrong JeanChief Scientific OfficerJan 28Sale58.367,000408,529855,219Jan 29 07:37 PM
Cui Jingrong JeanChief Scientific OfficerJan 27Sale57.667,000403,652862,219Jan 29 07:37 PM
Cui Jingrong JeanChief Scientific OfficerJan 15Sale53.1211,500610,853869,219Jan 17 05:10 PM
Cui Jingrong JeanChief Scientific OfficerJan 14Sale53.5618,500990,811880,719Jan 14 07:17 PM
Cui Jingrong JeanChief Scientific OfficerJan 13Sale52.8718,500978,073899,219Jan 14 07:17 PM
Cui Jingrong JeanChief Scientific OfficerJan 10Sale57.6818,5001,067,161917,719Jan 14 07:17 PM
Cui Jingrong JeanChief Scientific OfficerDec 20Sale63.4011,500729,150936,219Dec 20 06:29 PM
Cui Jingrong JeanChief Scientific OfficerDec 19Sale61.0918,5001,130,257947,719Dec 20 06:29 PM
Cui Jingrong JeanChief Scientific OfficerDec 18Sale59.2018,5001,095,170966,219Dec 20 06:29 PM
Cui Jingrong JeanChief Scientific OfficerDec 17Sale61.3218,5001,134,374984,719Dec 17 09:09 PM
Cui Jingrong JeanChief Scientific OfficerDec 16Sale58.3511,500671,0771,003,219Dec 17 09:09 PM
Cui Jingrong JeanChief Scientific OfficerDec 13Sale55.7511,500641,1691,014,719Dec 17 09:09 PM
Cui Jingrong JeanChief Scientific OfficerDec 12Sale54.1111,500622,2911,026,219Dec 12 07:54 PM
Cui Jingrong JeanChief Scientific OfficerDec 11Sale52.9411,500608,7871,037,719Dec 12 07:54 PM
Cui Jingrong JeanChief Scientific OfficerDec 10Sale54.5811,500627,6311,049,219Dec 12 07:54 PM
Cui Jingrong JeanChief Scientific OfficerDec 09Sale55.3211,500636,2291,060,719Dec 09 08:44 PM
Cui Jingrong JeanChief Scientific OfficerDec 06Sale50.7750,8902,583,5881,072,219Dec 09 08:44 PM
Cui Jingrong JeanChief Scientific OfficerDec 05Sale51.9556,1102,914,9361,123,109Dec 09 08:44 PM